Want to see NUVL full AI Analyst Report?
NUVL Stock Chart & Stats
$107.61
-$0.36(-0.45%)
At close: 4:00 PM EST
$107.61
-$0.36(-0.45%)
Day’s Range― - ―
52-Week Range$71.13 - $123.99
Previous CloseN/A
Volume65.93K
Average Volume (3M)4.05M
Market Cap
$9.79B
Enterprise Value$6.77K
Total Cash (Recent Filing)$1.29B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 06, 2026EPS Estimate
-1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.06
Shares Outstanding73,562,660
10 Day Avg. Volume1,623,780
30 Day Avg. Volume4,052,796
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)5.86
Price to Sales (P/S)0.00
P/FCF Ratio-26.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$125.26Price Target Upside16.40% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-5.64
Revenue Forecast (FY)$11.31M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero reported debt and roughly $1.17B of equity give the company durable financial flexibility to fund clinical programs and negotiations. Low leverage reduces refinancing risk, supports R&D spending cadence, and provides a buffer versus short-term funding shocks over the next several months.
Acquisition Agreement With GSKA signed merger agreement with GSK is a structural change that materially de-risks financing and commercialization paths: it brings large pharma capabilities, committed deal mechanics (tender/support agreements, no-financing contingency) and accelerates the route to market for late-stage assets.
Regulatory Milestone: NDA FilingAn FDA New Drug Application for neladalkib is a substantive, lasting development milestone that moves the lead program from trials to regulatory review. This increases the probability of near-term commercialization or deal value realization and strengthens long-term franchise prospects if approved.
Bears Say
Pre-revenue With Widening LossesBeing pre-revenue while incurring rapidly expanding R&D and operating losses creates a persistent profitability gap. Without product sales, the company depends on milestone outcomes or transaction execution to justify capital deployment and restore earnings potential over the medium term.
Accelerating Cash BurnDeeply negative free cash flow and accelerating burn imply ongoing reliance on external capital unless commercialization or a closing transaction occurs. Even with a strong balance sheet, sustained negative cash generation constrains optionality and increases execution risk over the next several quarters.
Concentrated, Late-stage Asset RiskThe business outcome hinges on a small number of late-stage candidates (ROS1, ALK). This concentration makes long-term prospects binary: regulatory setbacks, competition, or safety issues with one or both leads would materially harm future revenue potential and limit diversification.
Nuvalent News
NUVL FAQ
What was Nuvalent, Inc. Class A’s price range in the past 12 months?
Nuvalent, Inc. Class A lowest stock price was $71.13 and its highest was $123.99 in the past 12 months.
What is Nuvalent, Inc. Class A’s market cap?
Nuvalent, Inc. Class A’s market cap is $9.79B.
When is Nuvalent, Inc. Class A’s upcoming earnings report date?
Nuvalent, Inc. Class A’s upcoming earnings report date is Aug 06, 2026 which is in 19 days.
How were Nuvalent, Inc. Class A’s earnings last quarter?
Nuvalent, Inc. Class A released its earnings results on May 07, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.34 by -$0.05.
Is Nuvalent, Inc. Class A overvalued?
According to Wall Street analysts Nuvalent, Inc. Class A’s price is currently Undervalued.
Does Nuvalent, Inc. Class A pay dividends?
Nuvalent, Inc. Class A does not currently pay dividends.
What is Nuvalent, Inc. Class A’s EPS estimate?
Nuvalent, Inc. Class A’s EPS estimate is -1.41.
How many shares outstanding does Nuvalent, Inc. Class A have?
Nuvalent, Inc. Class A has 73,562,660 shares outstanding.
What happened to Nuvalent, Inc. Class A’s price movement after its last earnings report?
Nuvalent, Inc. Class A reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.34. Following the earnings report the stock price went down -1.784%.
Which hedge fund is a major shareholder of Nuvalent, Inc. Class A?
Currently, no hedge funds are holding shares in NUVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvalent Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$125.26 (16.40% Upside)
$125.26 (16.40% Upside)
Blogger Sentiment
Neutral
NUVL Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 310.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.7%
Last 30 Days ▼ 8.7%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-42.78%
Trailing 12-Months
Asset Growth
20.38%
Trailing 12-Months
Company Description
Nuvalent, Inc. Class A
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
NUVL Stock 12 Month Forecast
Average Price Target
$125.26
▲(16.40% Upside)
Technical Analysis
Ownership Overview
26.66% Insiders
31.41% Mutual Funds
0.23% Other Institutional Investors
29.10% Public Companies and
Individual Investors